Trajectory of Recovery and Burden of Residual Symptoms Following Guillain–Barré Syndrome: A Single-Center Prospective Cohort Study From Sri Lanka

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System Pub Date : 2026-02-24 DOI:10.1111/jns.70105

Bimsara Senanayake, Arun Rajaratnam, Thilani Thennakoon, Nimasha Ekanayake, Pramith Ruwanpathirana

{"title":"Trajectory of Recovery and Burden of Residual Symptoms Following Guillain–Barré Syndrome: A Single-Center Prospective Cohort Study From Sri Lanka","authors":"Bimsara Senanayake, Arun Rajaratnam, Thilani Thennakoon, Nimasha Ekanayake, Pramith Ruwanpathirana","doi":"10.1111/jns.70105","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>Guillain–Barré syndrome (GBS) is classically a monophasic illness. In resource-limited settings, patients with GBS are not routinely followed up. However, these patients may suffer from residual symptoms and disability. In this study, we assessed the trajectory of recovery and burden of residual symptoms in patients who developed GBS.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This prospective cohort study was conducted at the National Hospital of Sri Lanka from January 1, 2020 to April 1, 2025. We assessed the patients during the illness and then at 1, 3, and 6 months after discharge. The primary outcome was the GBS Disability Score (0 [<i>no disability</i>]–6 [<i>death</i>]), and the secondary outcomes were the individual residual symptoms. All patients with GBS were included. The serial improvement of the GBS Disability Score was assessed using the generalized equation estimate. The burden of residual symptoms was given as percentages.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We included 144 patients with GBS (mean age 46.2 ± 17.3 years; male:female 0.92), and 67 completed the follow-up. There was no in-hospital mortality; one patient (1.5%) died within 6 months. The disability improved significantly, with only 5.9% unable to walk independently at 6 months. Increasing age and axonal variants (AMAN/AMSAN, 37%) were independent negative predictors of recovery. The residual symptoms at 6 months included positive sensory symptoms (42.6%), fatigue (30.9%), and subjective limb weakness (29.4%). Forty-eight percent had to make some change in their occupation.</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>Although many patients achieve motor recovery, there is a high burden of residual symptoms at 6 months in patients with GBS.</p>\n </section>\n </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Peripheral Nervous System","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jns.70105","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aims

Guillain–Barré syndrome (GBS) is classically a monophasic illness. In resource-limited settings, patients with GBS are not routinely followed up. However, these patients may suffer from residual symptoms and disability. In this study, we assessed the trajectory of recovery and burden of residual symptoms in patients who developed GBS.

Methods

This prospective cohort study was conducted at the National Hospital of Sri Lanka from January 1, 2020 to April 1, 2025. We assessed the patients during the illness and then at 1, 3, and 6 months after discharge. The primary outcome was the GBS Disability Score (0 [no disability]–6 [death]), and the secondary outcomes were the individual residual symptoms. All patients with GBS were included. The serial improvement of the GBS Disability Score was assessed using the generalized equation estimate. The burden of residual symptoms was given as percentages.

Results

We included 144 patients with GBS (mean age 46.2 ± 17.3 years; male:female 0.92), and 67 completed the follow-up. There was no in-hospital mortality; one patient (1.5%) died within 6 months. The disability improved significantly, with only 5.9% unable to walk independently at 6 months. Increasing age and axonal variants (AMAN/AMSAN, 37%) were independent negative predictors of recovery. The residual symptoms at 6 months included positive sensory symptoms (42.6%), fatigue (30.9%), and subjective limb weakness (29.4%). Forty-eight percent had to make some change in their occupation.

Interpretation

Although many patients achieve motor recovery, there is a high burden of residual symptoms at 6 months in patients with GBS.

查看原文本刊更多论文

guillain - barr综合征后的恢复轨迹和残留症状负担：斯里兰卡的一项单中心前瞻性队列研究

背景和目的：吉兰-巴勒综合征（GBS）是一种典型的单相疾病。在资源有限的环境中，GBS患者没有常规随访。然而，这些患者可能会出现残留症状和残疾。在这项研究中，我们评估了GBS患者的康复轨迹和残留症状负担。方法：这项前瞻性队列研究于2020年1月1日至2025年4月1日在斯里兰卡国家医院进行。我们在患者患病期间以及出院后1、3、6个月对患者进行评估。主要结局是GBS残疾评分（0[无残疾]-6[死亡]），次要结局是个体残留症状。所有GBS患者均被纳入。采用广义方程估计评估GBS残疾评分的连续改善。残余症状负担以百分比表示。结果：144例GBS患者（平均年龄46.2±17.3岁，男：女0.92岁），67例完成随访。没有住院死亡率；1例（1.5%）患者在6个月内死亡。残疾明显改善，只有5.9%的患者在6个月时不能独立行走。年龄增加和轴突变异（AMAN/AMSAN, 37%）是恢复的独立负预测因子。6个月时残留症状包括阳性感觉症状（42.6%）、疲劳（30.9%）和主观肢体无力（29.4%）。48%的人不得不在职业上做出一些改变。解释：尽管许多患者实现了运动恢复，但GBS患者在6个月时的残留症状负担很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Peripheral Nervous System 医学-临床神经学

CiteScore

6.10

自引率

7.90%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of the Peripheral Nervous System is the official journal of the Peripheral Nerve Society. Founded in 1996, it is the scientific journal of choice for clinicians, clinical scientists and basic neuroscientists interested in all aspects of biology and clinical research of peripheral nervous system disorders. The Journal of the Peripheral Nervous System is a peer-reviewed journal that publishes high quality articles on cell and molecular biology, genomics, neuropathic pain, clinical research, trials, and unique case reports on inherited and acquired peripheral neuropathies. Original articles are organized according to the topic in one of four specific areas: Mechanisms of Disease, Genetics, Clinical Research, and Clinical Trials. The journal also publishes regular review papers on hot topics and Special Issues on basic, clinical, or assembled research in the field of peripheral nervous system disorders. Authors interested in contributing a review-type article or a Special Issue should contact the Editorial Office to discuss the scope of the proposed article with the Editor-in-Chief.